Aktie MEDGENICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Medgenics, Inc. Nyse

Aktien

US58436Q2030

Schlusskurs Nyse
Andere Börsenplätze
- USD - Intraday Chart für Medgenics, Inc.
2018 Transcript : Aevi Genomic Medicine, Inc. - Special Call
2018 Transcript : Aevi Genomic Medicine, Inc., Q4 2017 Earnings Call, Mar 13, 2018

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Aevi Genomic Medicine, LLC(NasdaqGM:GNMX) dropped from S&P TMI Index
AEVI GENOMIC MEDICINE, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
Aevi Genomic Medicine, Inc. Announces Resignation of Directors
Aevi Genomic Medicine, LLC(NasdaqCM:GNMX) dropped from NASDAQ Composite Index
Cerecor Inc. completed the acquisition of Aevi Genomic Medicine, Inc..
AEVI GENOMIC MEDICINE, INC. : Unregistered Sale of Equity Securities, Regulation FD Disclosure, Other Events (form 8-K)
AEVI GENOMIC MEDICINE : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K/A)
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
Aevi Genomic Medicine, Inc. Doses the First Patient with AEVI-002 in A Phase Ib Clinical Trial
AEVI GENOMIC MEDICINE, INC. : Other Events (form 8-K)
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement (form 8-K)
Aevi Genomic Medicine, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
Cerecor Inc. entered into a definitive merger agreement to acquire Aevi Genomic Medicine, Inc. for $15.6 million.
Aevi Genomic Medicine, Inc. : Receives Positive Nasdaq Listing Determination
Aevi Genomic Medicine, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019
Aevi Genomic Medicine : Enters into License Agreement with AstraZeneca for Anti-IL-18 Antibody
Aevi Genomic Medicine, Inc. Obtains License for Medi2338, Phase 2-Ready Fully Human Monoclonal Antibody That Targets Interleukin 18 (IL-18)
Aevi Genomic Medicine : to Present at the 2019 Wedbush PacGrow Healthcare Conference
Aevi Genomic Medicine : Enters into Worldwide License Agreement with Astellas to Develop and Commercialize a Novel Second Generation mTORC1/2 Inhibitor
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. Aktie
  4. Aktie
  5. Nachrichten Medgenics, Inc.
  6. Andere Sprachen
-40 % Einmalige Verlängerung: Unsere Abonnements führen Sie zu den besten Investitionen von morgen
PROFITIEREN SIE JETZT